Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS.

JAMA Oncol. 2019 Oct 10. doi: 10.1001/jamaoncol.2019.3343. [Epub ahead of print]

PMID:
31600397
2.

Physician Perceptions of the Use of Social Media for Recruitment of Patients in Cancer Clinical Trials.

Sedrak MS, Sun V, Liu J, George K, Wong AR, Dale W, Dizon DS.

JAMA Netw Open. 2019 Sep 4;2(9):e1911528. doi: 10.1001/jamanetworkopen.2019.11528.

3.

Distress: Characterizing What Causes the Thermometer to Shift in Patients with Newly Diagnosed Breast Cancer Attending a Multidisciplinary Clinic.

Ciambella CC, Taneja C, Dizon DS, Wiggins DL, Emmick CM, Leonard KL, Lopresti ML, Witherby S, Cabral D, Snow S, Graves TA.

Ann Surg Oncol. 2019 Oct;26(10):3204-3209. doi: 10.1245/s10434-019-07544-z. Epub 2019 Jul 24.

PMID:
31342366
4.

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities.

Katz MS, Anderson PF, Thompson MA, Salmi L, Freeman-Daily J, Utengen A, Dizon DS, Blotner C, Cooke DT, Sparacio D, Staley AC, Fisch MJ, Young C, Attai DJ.

JCO Clin Cancer Inform. 2019 Jun;3:1-10. doi: 10.1200/CCI.18.00124.

5.

Serum ferritin as a candidate diagnostic biomarker of polycystic ovarian syndrome: a meta-analysis.

Tiongco RE, Rivera N, Clemente B, Dizon D, Salita C, Pineda-Cortel MR.

Biomarkers. 2019 Jul;24(5):484-491. doi: 10.1080/1354750X.2019.1620335. Epub 2019 May 27.

PMID:
31096807
6.

Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer.

Yerramilli D, Drapek L, Nipp RD, Horick N, Moran SMC, Noé B, D'Arpino SM, Mitra D, Hong TS, Ryan DP, Dizon DS, Wo J.

J Gastrointest Cancer. 2019 Apr 13. doi: 10.1007/s12029-019-00233-w. [Epub ahead of print]

PMID:
30980294
7.

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.

Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS.

Gynecol Oncol. 2019 May;153(2):223-229. doi: 10.1016/j.ygyno.2019.02.004. Epub 2019 Feb 12.

PMID:
30765148
8.

ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma.

Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, Carneiro BA.

Oncotarget. 2019 Jan 4;10(2):245-251. doi: 10.18632/oncotarget.26521. eCollection 2019 Jan 4.

9.

Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG.

Dizon DS, Sedrak MS, Lewis MA, Cook E, Fisch MJ, Klemp JR, Sommers J, Ciccarella A, Gralow J, Lawton W, Nichols C; SWOG Digital Engagement Committee.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00122.

10.

Prostate Cancer Social Media: In YouTube We Trust?

Carneiro B, Dizon DS.

Eur Urol. 2019 Apr;75(4):568-569. doi: 10.1016/j.eururo.2019.01.004. Epub 2019 Jan 11. No abstract available.

PMID:
30639141
11.

The utility of real-time polymerase chain reaction in detecting Coccidioides immitis among clinical specimens in the Central California San Joaquin Valley.

Dizon D, Mitchell M, Dizon B, Libke R, Peterson MW.

Med Mycol. 2018 Nov 21. doi: 10.1093/mmy/myy111. [Epub ahead of print]

PMID:
30462288
12.

Protecting Patient Privacy in Narratives: The Lifespan-Brown Checklist for Appropriate Use of Patient Narratives.

Rafelson W, Bruno J, Dizon DS.

Oncologist. 2019 Mar;24(3):285-287. doi: 10.1634/theoncologist.2018-0659. Epub 2018 Nov 9. No abstract available.

PMID:
30413664
13.

Palliative Total Pelvic Exenteration for Gynecologic Cancers: A Cross-sectional Study of Society of Gynecologic Oncology Members.

MacLaughlan David S, Marjon N, English D, Purington N, Han SS, Dizon DS.

Int J Gynecol Cancer. 2018 Nov;28(9):1796-1804. doi: 10.1097/IGC.0000000000001371.

PMID:
30371565
14.

Survivorship care planning in gynecologic oncology-perspectives from patients, caregivers, and health care providers.

de Rooij BH, Thomas TH, Post KE, Flanagan J, Ezendam NPM, Peppercorn J, Dizon DS.

J Cancer Surviv. 2018 Dec;12(6):762-774. doi: 10.1007/s11764-018-0713-9. Epub 2018 Sep 12.

15.

Sexuality, fertility and pregnancy following breast cancer treatment.

Lopresti M, Rizack T, Dizon DS.

Gland Surg. 2018 Aug;7(4):404-410. doi: 10.21037/gs.2018.01.02. Review.

16.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM.

Gynecol Oncol. 2018 Nov;151(2):202-207. doi: 10.1016/j.ygyno.2018.08.006. Epub 2018 Aug 31.

PMID:
30174176
17.

Contemporary Approaches to High-risk, Early-Stage Serous Endometrial Cancer: Clinical Equipoise Persists.

Bandera C, Dizon DS.

Am J Clin Oncol. 2019 Feb;42(2):107-108. doi: 10.1097/COC.0000000000000475. No abstract available.

PMID:
29965808
18.

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA.

Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24.

19.

Cluster Analysis Demonstrates the Need to Individualize Care for Cancer Survivors.

de Rooij BH, Park ER, Perez GK, Rabin J, Quain KM, Dizon DS, Post KE, Chinn GM, McDonough AL, Jimenez RB, van de Poll-Franse LV, Peppercorn J.

Oncologist. 2018 Dec;23(12):1474-1481. doi: 10.1634/theoncologist.2017-0558. Epub 2018 May 8.

PMID:
29739897
20.

The Needs of Women Treated for Ovarian Cancer: Results From a #gyncsm Twitter Chat.

Thomas TH, Nauth-Shelley K, Thompson MA, Attai DJ, Katz MS, Graham D, Sparacio D, Lizaso C, Utengen A, Dizon DS.

J Patient Cent Res Rev. 2018 Apr 26;5(2):149-157. doi: 10.17294/2330-0698.1592. eCollection 2018 Spring.

21.

Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation.

El-Jawahri A, Fishman SR, Vanderklish J, Dizon DS, Pensak N, Traeger L, Greer JA, Park ER, Markovitz N, Waldman L, Hunnewell C, Saylor M, Driscoll J, Li Z, Spitzer TR, McAfee S, Chen YB, Temel JS.

Cancer. 2018 Jun 1;124(11):2438-2446. doi: 10.1002/cncr.31333. Epub 2018 Mar 14.

22.

Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation.

Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M.

Oncologist. 2018 Jun;23(6):650-653. doi: 10.1634/theoncologist.2017-0526. Epub 2018 Feb 22.

23.

Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic.

Wo JY, Drapek LC, Niemierko A, Silvia B, Noé BN, Russo AL, Miyamoto DT, Hong TS, Efstathiou JA, Zietman AL, Dizon DS.

Pract Radiat Oncol. 2018 May - Jun;8(3):206-212. doi: 10.1016/j.prro.2017.11.004. Epub 2017 Nov 21.

PMID:
29426693
24.

Mindfulness in nursing students: The five facet mindfulness questionnaire in samples of nursing students in China, the Philippines, and South Africa.

Arthur D, Dizon D, Jooste K, Li Z, Salvador M, Yao X.

Int J Ment Health Nurs. 2018 Jun;27(3):975-986. doi: 10.1111/inm.12405. Epub 2017 Dec 15.

PMID:
29243377
25.

Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine.

Attai DJ, Anderson PF, Fisch MJ, Graham DL, Katz MS, Kesselheim J, Markham MJ, Pennell NA, Sedrak MS, Thompson MA, Utengen A, Dizon DS; Collaboration for Outcomes on Social Media in Oncology (COSMO).

Semin Hematol. 2017 Oct;54(4):198-204. doi: 10.1053/j.seminhematol.2017.08.001. Epub 2017 Aug 12. Review.

26.

Twitter 101 and beyond: introduction to social media platforms available to practicing hematologist/oncologists.

Thompson MA, Ahlstrom J, Dizon DS, Gad Y, Matthews G, Luks HJ, Schorr A.

Semin Hematol. 2017 Oct;54(4):177-183. doi: 10.1053/j.seminhematol.2017.06.006. Epub 2017 Jul 11. Review.

PMID:
29153077
27.

PARP inhibitors for targeted treatment in ovarian cancer.

Dizon DS.

Lancet. 2017 Oct 28;390(10106):1929-1930. doi: 10.1016/S0140-6736(17)32418-2. Epub 2017 Sep 12. Review. No abstract available.

PMID:
28916370
28.

What's the Harm?

Dizon DS.

Oncologist. 2017 Jul 24. pii: theoncologist.2017-0280. doi: 10.1634/theoncologist.2017-0280. [Epub ahead of print] No abstract available.

29.

Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter?

Gass JS, Onstad M, Pesek S, Rojas K, Fogarty S, Stuckey A, Raker C, Dizon DS.

Ann Surg Oncol. 2017 Oct;24(11):3133-3140. doi: 10.1245/s10434-017-5905-4. Epub 2017 Jun 12.

PMID:
28608119
30.

The emerging role of professional social media use in oncology.

Sedrak MS, Dizon DS, Anderson PF, Fisch MJ, Graham DL, Katz MS, Kesselheim JC, Miller RS, Thompson MA, Utengen A, Attai DJ; Collaboration for Outcomes on Social Media in Oncology (COSMO).

Future Oncol. 2017 Jun;13(15):1281-1285. doi: 10.2217/fon-2017-0161. Epub 2017 Jun 7. No abstract available.

31.

How to Address Sexual Problems in Female Cancer Patients.

Preti EP, Landoni F, Colombo N, Dizon DS.

Oncology (Williston Park). 2017 Apr 15;31(4):258-62, 264.

32.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

33.

Axillary Ultrasound Fine Needle Aspiration Biopsy: Is There a Role in the Post Z-0011 Era?

Pesek SE, King HM, Koelliker S, Raker C, Edmonson D, Dizon DS, Gass J.

Am J Clin Oncol. 2018 Jul;41(7):702-707. doi: 10.1097/COC.0000000000000345.

PMID:
28338482
34.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
35.

Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.

Dizon DS.

Gynecol Oncol. 2017 Feb;144(2):241-242. doi: 10.1016/j.ygyno.2016.12.020. Epub 2017 Jan 3. No abstract available.

PMID:
28062117
36.

Reply to the letter to the editor 'Integrating communication as a core skill in the global curriculum for medical oncology' by Horlait et al.

Dittrich C, Stiefel F, Kiss A, Dizon DS.

Ann Oncol. 2017 Apr 1;28(4):905-906. doi: 10.1093/annonc/mdw679. No abstract available.

PMID:
28049138
37.

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J.

J Natl Compr Canc Netw. 2017 Jan;15(1):92-120.

PMID:
28040721
38.

A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.

McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C.

Gynecol Oncol. 2017 Jan;144(1):101-106. doi: 10.1016/j.ygyno.2016.10.026. Epub 2016 Oct 28.

39.

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).

Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM.

Ann Oncol. 2017 Mar 1;28(3):505-511. doi: 10.1093/annonc/mdw635.

40.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

41.

Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.

Bychkovsky BL, Dizon DS, Sikov WM.

Clin Obstet Gynecol. 2016 Dec;59(4):756-771. Review.

PMID:
27741213
42.

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

Gynecol Oncol. 2016 Oct;143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. Epub 2016 Aug 8.

43.

Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer.

Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA Jr, Banerji A.

J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):177-178. doi: 10.1016/j.jaip.2016.07.010. Epub 2016 Sep 15. No abstract available.

PMID:
27641482
44.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

J Clin Oncol. 2016 Oct 1;34(28):3460-73. doi: 10.1200/JCO.2016.68.6907. Epub 2016 Aug 8.

45.

Neoadjuvant chemotherapy for advanced epithelial ovarian cancer.

Hall TR, Dizon DS.

Clin Adv Hematol Oncol. 2016 Apr;14(4):262-8. Review.

PMID:
27166608
46.

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.

Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ.

Ann Oncol. 2016 Apr;27 Suppl 1:i4-i10. doi: 10.1093/annonc/mdw083. Review.

47.

Social media in cancer care: highlights, challenges & opportunities.

Attai DJ, Sedrak MS, Katz MS, Thompson MA, Anderson PF, Kesselheim JC, Fisch MJ, Graham DL, Utengen A, Johnston C, Miller RS, Dizon DS; Collaboration for Outcomes on Social Media in Oncology (COSMO).

Future Oncol. 2016 Jul;12(13):1549-52. doi: 10.2217/fon-2016-0065. Epub 2016 Mar 30. No abstract available.

PMID:
27025657
48.

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.

Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ.

Gynecol Oncol. 2016 Apr;141(1):108-12. doi: 10.1016/j.ygyno.2016.02.032.

PMID:
27016236
49.

Chemotherapy in ovarian germ cell tumors: A systematic review.

Simone CG, Markham MJ, Dizon DS.

Gynecol Oncol. 2016 Jun;141(3):602-607. doi: 10.1016/j.ygyno.2016.02.007. Epub 2016 Feb 9. Review.

PMID:
26873864
50.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G.

J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4. No abstract available.

Supplemental Content

Support Center